The FDA, Moderna and the politics of regulatory science

THE PENDING FDA decision on Moderna's mRNA flu vaccine is about more than one biotech's product launch. It is a test of whether an American regulatory agency can resist political interference in its scientific work.

The Food and Drug Administration reaches its PDUFA deadline today - the date by which it must approve, reject, or extend its review of Moderna's mRNA-1010. The advisory committee recommended approval unanimously on June 18th, voting 9-0. The scientific case appears solid: a Phase III trial of 22,502 adults aged 50 and older showed the vaccine reduced the likelihood of influenza illness by approximately 27% compared to a standard-dose seasonal flu shot. If approved, the vaccine would be the first mRNA-based flu vaccine to reach the American market. Moderna, a company that has burned through much of its COVID-era cash, would finally have a pipeline asset that could begin to replace the revenue that disappeared with the pandemic.

Yet the road to this moment was anything but routine. In February, the FDA refused to even file Moderna's application - a rare rebuke that sent shockwaves through the biotech industry. The reason was not safety or efficacy. The agency claimed Moderna's trial had not compared its vaccine against the "best-available standard of care," meaning Moderna should have used a higher-dose flu vaccine as the control for participants aged 65 and older, rather than the standard dose that had been approved for all adults. The trouble is that the FDA itself had reviewed and accepted Moderna's trial design before the study began.

The refusal was not the work of career scientists. It was ordered by Vinay Prasad, then the FDA's top vaccine official, who had overruled the agency's own Office of Vaccines Research and Review - at least the fourth time he had done so, according to The Conversation. Mr Prasad, along with former FDA commissioner Marty Makary, has since left the agency, replaced by what appears to be more traditional leadership. A week after the initial refusal, and following a public outcry, the FDA reversed course. Moderna agreed to a revised regulatory path: full approval for adults aged 50 to 64, accelerated approval for those 65 and older, conditional on a post-marketing confirmatory study.

To be sure, the FDA's concern was not entirely baseless. Seasonal flu vaccines are known to be less effective in older, frailer patients, and higher-dose formulations exist precisely to address that gap. Asking for stronger evidence in the most vulnerable cohort is reasonable in principle. The problem was not the standard; it was the timing. Imposing a new comparator requirement after accepting the trial protocol, and after the data had been collected, is not how regulatory science is supposed to work. It turns rules into moving targets.

The institutional damage was real. At roughly the same time, the Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., cancelled nearly $500m in mRNA research funding. Mr Kennedy has long expressed scepticism about mRNA vaccines without offering credible data on their risks. The combination of regulatory uncertainty and defunding had a chilling effect. Jeff Coller, a professor at Johns Hopkins University who has studied mRNA technology for decades, put it plainly: "When you see the FDA rejecting a product that comes from Moderna, why is it that my little company would be able to push through?" Moderna is the largest player in a space mostly populated by small biotechs with 20 or 30 employees. When the agency signals hostility toward the category leader, the message is read as a sector-wide warning. Moderna's president, Stephen Hoge, told NPR that the company is holding off on some planned mRNA research until it knows how things will shake out.

This is where the economics of the case come into focus. Moderna is a company in transition, and a strained one. In the second quarter of 2026, revenue was $145m, against a net loss of $782m. The company guided for year-end cash of between $4.7bn and $5.2bn and has cut its operating expense outlook - signs of a firm trying to extend its runway while waiting for its pipeline to pay off. Revenue has collapsed from the COVID peak: in the third quarter of 2024, it was $1.86bn; two years later, it is a fraction of that. The share price has recovered sharply this year, up roughly 92% so far, but the company remains deeply loss-making. AInvest's aggregate signal labels the stock a Hold, reflecting a market that sees catalysts but is unwilling to price in certainty.

For investors, the relevant risk is not whether Moderna's flu vaccine works. The Glow trial's results, published in the New England Journal of Medicine, are credible enough that even FDA staff reviewers identified no major deficiencies. The question is whether an approval translates into meaningful revenue, and whether the regulatory whiplash this episode created will slow the pipeline elsewhere. Flu vaccines are a crowded space. Seasonal flu shots are cheap, widely administered, and already entrenched. An mRNA flu vaccine's advantage - speed of development, the ability to update formulations quickly to match emerging strains - matters more for future pandemics than for annual seasonal protection. The commercial prize, if it exists, may come later, through pandemic readiness, combination vaccines, or platform licensing, rather than from displacing existing flu-shot makers.

The broader lesson concerns institutions. Regulators exist to separate science from politics. When political appointees overrule career scientists on procedural grounds, the result is not higher standards; it is uncertainty, delayed products, and a chill on innovation. The FDA eventually backed down in this case. That is welcome. But a regulatory system that requires public outcry and political turnover to restore basic norms is already broken.

The decision today will determine whether Moderna gets its flu vaccine to market for the 2026-27 season. It should also serve as a reminder that institutional credibility is not inherited. It is maintained, quarter by quarter, by refusing to let politics write the science.